Patients with advanced stage non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line treatment had better progression-free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin-related (rash, xerosis and paronychia) and gastrointestinal-related (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild. But severe cases can occur, significantly affecting patient's well-being, treatment compliance and quality of life. Therefore, patient education, early diagnosis, and prophylactic treatment are important strategies to optimally manage EGFR TKI-related adverse effects. In this review, we summarize the commonly encountered EGFR TKI-related AEs and provide a current overview of AE management in local practice with a focus on Asian patients.
TA B L E 1 Time of onset and incidence of skin and gastrointestinal AE with treatments for non-small cell lung cancer In this review, we provide an overview of the commonly occurring cutaneous and gastrointestinal AEs related to EGFR TKI treatment. In addition, we summarize the preventative and therapeutic measures for these AEs that are commonly practiced in Singapore. As it is also widely accepted that there are differences in skin biology between Asians and Caucasians, we would focus our discussion on Asian patients as earlier similar publications covered the Caucasian population. 5, 6 We would place emphasis on patients who were treated with EGFR TKI as first line as they are more susceptible to AEs compared to patients in later line settings. Management of EGFR TKI-related AE is generally the same across the three TKIs although practices on the type of antibiotics and steroids used and when these are prescribed can vary.
The third-generation TKIs include as osimertinib (AZD9291), rociletinib (CO-1686), HM61713 (olmutinib), EGF816 and ASP8273 are mutant selective, targeting sensitizing EGFR mutations as well as T790M EGFR and is WT EGFR sparing, resulting in less off-target toxicities. Of the agents in this class, only osimertinib has been approved for advanced NSCLC with EGFR T790M mutation following acquired resistance to first-or second-generation EGFR TKIs. As such, we will include discussions on the management of AEs related to this agent.
Given the mechanism of action, the AEs related to EGFR blockade with osimertinib such as skin rash, xerosis and paronychia are predictably lower than the previous generation of EGFR TKIs ( Table 1 ). The frequency of diarrhea is 24-41% but grade 3 or more is rare (1-2%). [7] [8] [9] The principles of management of AEs related to the first-and secondgeneration EGFR TKIs can be applied to osimertinib.
COMMONLY OCCURRING EGFR TKI-RELATED CUTANEOUS AES
As EGFR is involved in epithelial maintenance (i.e. epidermal growth, differentiation, wound healing and keratinocyte migration), it is critical in the physiology and development of the epidermis (which is composed primarily of keratinocytes). 5, 10 An EGFR TKI impairs ker- [12] [13] [14] [15] As data on the time to onset for osimertinib is not available, we only report on the frequency of cutaneous AE that was recently revealed in the AURA3 trial. 7
Papulopustular (acneiform) rash
The earliest and most common EGFR TKI-related cutaneous AE is acneiform rash. The eruption generally evolves through four distinct phases 10, 16 : (1) dysesthesia, erythema and edema as early as 1-2 weeks of first-and second-generation EGFR TKI treatment; (2) erythematous papules and pustules; (3) purulent crusts at 3-6 weeks and (4) telangiectasias. Patients will experience waxing and waning of lesions during the clinical course. Lesions can be painful and pruritic. Symptoms typically resolved within 4 weeks after EGFR TKI is ceased; but there could be partial or even complete resolution despite continued EGFR TKI therapy. Because EGFRs are highly expressed in sebaceous epithelium, eruptions are generally most concentrated in seborrheic areas such as the scalp, face, neck, chest and upper back. The periorbital region, palms and soles are usually spared. 17 The different degrees of severity of the papulopustular rash are illustrated in 
Xerosis
Abnormal keratinocyte differentiation due to EGFR TKIs can impair the epidermal barrier, decreasing loricrin, the main protein forming the scaffold for the epidermis. 18, 19 21 There have also been incidences of severe cases of pulpitis sicca with painful rhagades.
Paronychia
Between 10 and 15% of first and second generations EGFR TKI patients have paronychia; and this condition typically occurs later during treatment (i.e. 4-8 weeks). 22 Paronychia is graded by sever- The big toe is commonly the first area to be affected, and when pyogenic granuloma develops on the nail fold, patient can experience severe pain. 23 Nail matrix inflammation may result in onycholysis or onychodystrophy.
Scalp lesions
The EGFR TKIs have been linked to severe scalp inflammation and hair loss (scarring or non-scarring alopecia). [24] [25] [26] [27] Folliculitis decalvans is a severe form of scarring involving the scalp. 20 Generally, 5-6% of the patients develop alopecia 2-4 months after therapy is started, whereas hirsutism (hair curling and rigidity, facial hypertrichosis and trichomegaly) can appear 1-2 months after therapy is started. If trichomegaly involves the eyelashes, eye irritation and conjunctivitis can occur. [28] [29] [30] Alopecia associated with EGFR TKI primarily consists of catagen/telogen hair follicles and different inflammatory infiltrates. [24] [25] [26] [27] 31 
COMMONLY OCCURRING EGFR TKI-RELATED GASTROINTESTINAL AES
The squamous epithelium covering the tongue, esophagus and gastrointestinal tract can be affected by AEs caused by EGF deficiency. 32 Gastrointestinal symptoms associated with EGFR TKI therapy such as oral complications and diarrhea will be discussed in this section of the review.
Oral complications
Oral mucotitis and stomatitis are the most common EGFR TKI-related AEs affecting the mucous membrane of the gastrointestinal tract and oral cavity. A patient with oral mucositis may have extensive erythema or aphthous-like stomatitis. 20 Older patients and patients who have poor dental hygiene or uses dentures are more prone to develop these complications. 6 Majority of stomatitis/mucositis cases are mild, but can be very painful and make eating and drinking difficult for the patient.
Diarrhea
EGFR TKIs-related diarrhea are caused by the presence of EGFR on epithelial cells, particularly the GI tract. 3 We refer to CTCAE v4.03 for the description of the various grades of diarrhea. Briefly, grade 1, 2 and 3 refers to the increase of less than 4, 4 to 6 and more than 7 stools per day over baseline, respectively. Table 1 describes the frequency of diarrhea between the various first and second generation EGFR TKIs.
However, the mechanisms underlying diarrhea associated with EGFR TKI therapy remain poorly understood. It was proposed that excess chloride secretion during EGFR TKI treatment causes a secretory form of diarrhea. 33 Conversely, it was thought that EGFR TKI-associated diarrhea is caused by multiple factors, such as changes in gut motility; damage in the colonic crypt and altered intestinal microflora. 34 In our routine practice, we observed that afatinib induced diarrhea earlier during treatment compared to first generation EGFR TKI. More than half of our patients experience diarrhea within 2 to 3 days of therapy and around 70% of patients by 14 days.
Managing EGFR TKI-related AEs
Patient education is an important element in managing AEs. Physicians should educate patients on how frequent and how intense specific AEs can be, as well as the consequences of delaying treatment.
Optimal management of AEs are based on prophylaxis, which includes pre-emptive interventions that address frequently occurring toxicities, close patient monitoring, assessment of risk factors, early detection, severity grading and early intervention.
AEs in some patients may require a dose modification strategy in which the dose of TKIs is reduced/adjusted or discontinued; and then reintroduced at a lower dose once the AE improves to a lower grade. The dose reduction strategies are different among the various TKIs; and the management of AEs at various grades may be different according to the product information. A major concern for dose titration is that the drug could be less efficacious because of the suboptimal dosage. This issue was addressed in a combined post hoc analysis of the LUX-Lung 3, LUX-Lung 6 35 and LUX-Lung 7 36 studies, which showed that dose reduction of afatinib had limited effects on its efficacy. Patients whose dose was reduced within the first 6 months of treatment had similar median progression free survival (mPFS) as the cohort which remained on the indicated dose of 40 mg. 
Management of skin rash
The standard of care for managing rash includes topical and oral corticosteroids or antibiotics (lesions can be superinfected by bacteria). The management of EGFR-TKI induced skin toxicity is different between
Caucasian and Asian population considering that the difference in skin sensitivity and higher likelihood of developing post-inflammatory hyper-pigmentation (PIH). 38 Table 2 The tetracycline antibiotics are thought to reduce the incidence of EGFR TKI-related skin rash without impacting efficacy through antiinflammatory properties. 41 A systematic review and meta-analysis of 13 studies revealed 50% reduction in rash from all grade and As aboveIf infection is suspected (yellow crusts, purulent discharge or painful skin):
TA B L E 2 Recommended management of various skin conditions in lung cancer patients receiving EGFR TKI-targeted therapies in Singapore
• Anti-Staphylococcal antibiotic (cloxacillin 500 mg QDS, cephalexin 500 mg TDS) for 7 days
• Consider skin swab for bacterial culture • Silver nitrate applications to treat exuberant granulation tissue.
• Refer to podiatrist/dermatologist for physical treatments.
• Consider long-term prophylactic anti-inflammatory antibiotic eg doxycycline 3 70% reduction in severe grade rash, as well as a 40% reduction in paronychia. 42 In terms of patient education, physicians should inform patients to avoid exposure to direct sunlight and wear protective clothes covering the head, face, hands, arms and legs. 43 In addition, a sunscreen with dual UVA/UVB protection should be generously applied at least four-hourly whenever exposure to the sun is a possibility (more frequent application may be necessary for patients who sweat excessively or during swimming). Sun protection becomes even more important if a tetracycline drug is prescribed as primary prophylaxis.
Management of xerosis and/or pruritus
Patients who develop pruritus may benefit from topical, oral or systemic agents such as steroids, antihistamines or GABA agonists. 43 They can use hydroxyzine (50 mg) at night and a nonsedative antihistamine during the day. 6 A suitable moisturizer should be used regularly to treat xerosis. 43 At least 200-300 g of moisturizer cream per week is highly recommended. 44 One review suggested using urea-free softening cream after showers and a medium strength corticoid. 6 The clinical management of xerosis and/or pruritus in Singapore is summarized in Table 2 .
In terms of patient education, patient should be advised to use moisturizers to prevent dryness. 43 Soaps and detergents with strong scents should be avoided. Patients should be advised to bathe in cool or lukewarm water and to avoid long, hot showers. Sheets, clothing and undergarments should be washed using a mild detergent. Wool and other types of fabrics that can make the skin itch are best avoided; instead loose-fitting cotton clothing or other soft fabrics are recommended for regular wear. As dry air can dehydrate the skin, a humidifier can be considered indoors. Cold compresses can be directly applied over itchy areas for comfort.
Management of paronychia
Patients with paronychia can benefit from topical antibiotics/antiseptics and silver nitrate. Table 2 .
In terms of patient education, patient should be advised against biting and traumatizing their nails, aggressive manicures/pedicures as well as contact with irritating substances. 43, 45, 46 Prolonged exposure to water should also be avoided. If the patient has to wear vinyl gloves, they should use cotton gloves underneath. High-risk patients (diabetics/immunosuppressed patients) and patients repeatedly exposed to moist environments (housekeepers, swimmers, etc.) should take extra precautions to ensure their nails are dry and clean.
Management of stomatitis/mucositis
Prophylactic treatment of stomatitis / mucositis is highly recommended. There are no conclusive data evaluating treatment for these conditions, but experts recommend advising patients with general mouth sensitivity to gargle with a benzydamine rinse. 5 Triamcinolone in dental paste can be used for grade 1 stomatitis / mucositis. For grade 2, oral erythromycin or minocycline should be added. 5 For grade 3, triamcinolone should be substituted with clobetasol ointment and the dose of oral erythromycin/minocycline should be increased.
Patients should be educated on dental hygiene and food. They should see a dental surgeon before treatment is initiated to diagnose and manage all infections or denture problems, except for removing tartar. 43 In terms of patient education, patients should be advised to care for their oral health by using a brush with soft bristles, sodium bicarbonate and alcohol-free mouthwash; taking special care of dentures as they can cause oral sores. 47, 48 Food should be consumed cold or at room temperature, and food that is acidic, spicy, salty or coarse should be avoided. Patients should drink a lot of water, preferably using a straw to sip liquids. Dry lips should be managed using a lip balm or petroleum jelly. Whenever needed, patients can numb the mouth with ice chips or flavored ice pops.
Management of diarrhea
Loperamide is considered the mainstay pharmacologic treatment for diarrhea; with doses escalated to the highest recommended approved dose as needed. 49 Loperamide, a synthetic oral opioid drug, prolongs the transit time of intestinal contents, decreases daily fecal volume and improves its viscosity and bulk density, as well as diminishes the loss of fluid and electrolytes. Treating physicians should closely follow-up with patients approximately 3 days after the initiation of EGFR TKI therapy.
As with dermatological AEs, each EGFR TKI has specific instructions on dose reduction to overcome drug-induced diarrhea. The following describes the common dose reduction practices for patients prescribed afatinib, which is known to induce diarrhea early (i.e. Certain risk factors have been linked with a higher incidence of grade 3 diarrhea in afatinib-treated patients starting afatinib dose of 50 mg/day. These include a low (<50 kg) bodyweight, female gender and baseline renal impairment (creatinine clearance ≤80 mL/min).
These factors may be useful in predicting the development of diarrhea. However, these observations are based on small patient numbers and should be confirmed in larger sample sizes. Although early and appropriate treatment for afatinib-associated diarrhea appears to be essential, data to support the routine implementation of prophylactic treatment is still inconclusive. Management strategies to reduce the severity, or eliminate diarrhea entirely, are advocated to avoid reducing the dose of afatinib or the need to change the regimen if a clinical response is likely. 37 
CONCLUSION
The EGFR TKIs has changed the treatment paradigm for advanced NSCLC, providing patients with better efficacy and quality of life than chemotherapy. The EGFR TKIs also have favorable toxicity profiles, 
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